Early-phase clinical trials for patients with progressive or relapsed MB have evaluated the efficacy of FDA-approved immune checkpoint inhibitors, such as anti-PD-(L)1, which aim to enhance T-cell recognition and elimination of tumor cells (NCT02359565 and NCT03130959). This evidence concerns the gene CD274 and neoplasm.